We propose to rationally design, synthesize and test a series of advanced bioadhesive microbicidal vehicles which are triggered to undergo changes in their rheological properties by contact with seminal proteases. In fact, the same proteases that cause the liquefaction of the semen will cause liquefaction of the gel microbicide. We believe this approach will drastically increase the bioavailability of active anti-HIV components when they are needed most, by increasing transport properties without compromising coating. These materials will be constructed of bioresponsive polymers that in themselves are active or are formulated to contain active agents. This project is amongst the first to apply contemporary polymer synthesis methods, knowledge of bioresponsive polymer systems, and recent understanding of formulations and drug delivery in the vagina, to the compelling problem of development of microbicides for HIV prevention. Our approach addresses the physiology of the vagina and coitus, and then engineers materials which respond to environmental changes throughout their deployment life cycle. This will result in what we believe will be highly efficacious next generation microbicidal delivery vehicles. The bioresponsive formulations will be engineered to enhance the normal physiology of the vagina, to efficiently spread and adhere to tissue, and to provide a protective microbicidal coating. Moreover, the formulations will be designed to undergo sol-to-gel-to-sol phase transitions in response to physiological changes during deployment: i) topically applied as a low viscosity fluid, ii) triggered to gel by mixing of two components, thus forming a retained protective coating, and iii) undergoing reduction in viscosity, but not surface coating, through polymer structural changes triggered by contact with semen.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI062445-01
Application #
6844423
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Ruiz, Monica S
Project Start
2004-09-30
Project End
2006-08-31
Budget Start
2004-09-30
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$243,434
Indirect Cost
Name
University of Utah
Department
Biomedical Engineering
Type
Schools of Engineering
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Mahalingam, Alamelu; Jay, Julie I; Langheinrich, Kristofer et al. (2011) Inhibition of the transport of HIV in vitro using a pH-responsive synthetic mucin-like polymer system. Biomaterials 32:8343-55
Mahalingam, Alamelu; Geonnotti, Anthony R; Balzarini, Jan et al. (2011) Activity and safety of synthetic lectins based on benzoboroxole-functionalized polymers for inhibition of HIV entry. Mol Pharm 8:2465-75
Clark, Meredith R; Aliyar, Hyder A; Lee, Chang-won et al. (2011) Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles. Int J Pharm 413:10-18
Jay, Julie I; Lai, Bonnie E; Myszka, David G et al. (2010) Multivalent benzoboroxole functionalized polymers as gp120 glycan targeted microbicide entry inhibitors. Mol Pharm 7:116-29
Jay, Julie I; Shukair, Shetha; Langheinrich, Kristofer et al. (2009) Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater 19:2969-2977
Gupta, Kavita M; Barnes, Scott R; Tangaro, Rachel A et al. (2007) Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles. J Pharm Sci 96:670-81